Idiosyncratic toxicity: The role of toxicophores and bioactivation

Drug Discovery Today

Volumn 8, Issue 22, 2003, Pages 1044-1050

  Williams, Dominic P ^a   Park, B Kevin ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Bioactivation; Biochemistry; Drug Discovery; Metabolites; Pharmaceutical Science; Toxicity; Toxicophores; Transcription factors

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; BROMFENAC; CHLORPROMAZINE; CLOZAPINE; DICLOFENAC; DRUG METABOLITE; FUROSEMIDE; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OLANZAPINE; OLTIPRAZ; PARACETAMOL; PHENOTHIAZINE DERIVATIVE; PROTEIN; QUINONE DERIVATIVE; QUINONEIMINE; SULFAMETHOXAZOLE; SULFONAMIDE; SULFORAPHANE; THIOL; UNCLASSIFIED DRUG;

AGRANULOCYTOSIS; BLOOD DYSCRASIA; CATALYSIS; DOSE RESPONSE; DRUG ACTIVATION; DRUG CONJUGATION; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG TOXICITY; DRUG TRANSFORMATION; FEVER; HEPATITIS; HUMAN; LIVER FAILURE; LIVER FUNCTION TEST; LIVER TOXICITY; LIVER TRANSPLANTATION; METABOLITE; NEPHRITIS; NITRATION; NONHUMAN; PROTEIN INTERACTION; PROTEIN MODIFICATION; RASH; REVIEW;

BIOTRANSFORMATION; DRUG EVALUATION, PRECLINICAL; DRUG HYPERSENSITIVITY; DRUG TOXICITY; HUMANS; PHARMACEUTICAL PREPARATIONS;

EID: 0346250848     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(03)02888-5     Document Type: Review

References (72)

1. Lazarou J., et al. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. J. Am. Med. Assoc. 279:1998;1200-1205.
2. Pirmohamed M., et al. Adverse drug reactions: current status. BMJ. 316:1998;1295-1298.
3. Park B.K., et al. Advances in molecular toxicology-towards understanding idiosyncratic drug toxicity. Toxicology. 153:2000;39-60.
4. Meadows M. Serious liver injury. Leading reason for drug removals, restrictions. FDA Consum. 35:2001;8-9.
5. Michelson S., Joho K. Drug discovery, drug development and the emerging world of pharmacogenomics: prospecting for information in a data-rich landscape. Curr. Opin. Mol. Ther. 2:2000;651-654.
6. Friedman M.A., et al. The safety of newly approved medicines: do recent market removals mean there is a problem? J. Am. Med. Assoc. 281:1999;1728-1734.
7. Nelson S.D. Structure toxicity relationships-how useful are they in predicting toxicities of new drugs? Adv. Exp. Med. Biol. 500:2001;33-43.
8. Reid W.D., et al. Bromobenzene metabolism and hepatic necrosis. Pharmacology. 6:1971;41-55.
9. Fisher R., et al. Correlation of metabolism, covalent binding and toxicity for a series of bromobenzene derivatives using rat liver slices in vitro. Chem. Biol. Interact. 88:1993;191-198.
10. Slaughter D.E., Hanzlik R.P. Identification of epoxide- and quinone-derived bromobenzene adducts to protein sulfur nucleophiles. Chem. Res. Toxicol. 4:1991;349-359.
11. Monks T.J., et al. Bromobenzene and p-bromophenol toxicity and covalent binding in vivo. Life Sci. 30:1982;841-848.
12. Smith C.V., et al. Free radicals in vivo. Covalent binding to lipids. Mol. Pharmacol. 26:1984;112-116.
13. Liu J., et al. The nitric oxide donor, V-PYRRO/NO, protects against acetaminophen-induced hepatotoxicity in mice. Hepatology. 37:2003;324-333.
14. Lau S.S., Monks T.J. The contribution of bromobenzene to our current understanding of chemically-induced toxicities. Life Sci. 42:1988;1259-1269.
15. Jollow D.J., et al. Bromobenzene-induced liver necrosis. Protective role of glutathione and evidence for 3,4-bromobenzene oxide as the hepatotoxic metabolite. Pharmacology. 11:1974;151-169.
16. Thor H., et al. Biotransforamtion of bromobenzene to reactive metabolites by isolated hepatocytes. Witmer D.M. Biological Reactive Intermediates. 1982;287-298 Plenum, New York.
17. Cribb A.E., et al. Adverse reactions to sulphonamide and sulphonamide-trimethoprim antimicrobials: clinical syndromes and pathogenesis. Adverse Drug React. Toxicol. Rev. 15:1996;9-50.
18. Cribb A.E., et al. Covalent binding of sulfamethoxazole reactive metabolites to human and rat liver subcellular fractions assessed by immunochemical detection. Chem. Res. Toxicol. 9:1996;500-507.
19. Nassif A., et al. Drug-specific cytotoxic T lymphocytes in the skin lesions of a patient with toxic epidermal necrolysis. J. Invest. Dermatol. 118:2002;728-733.
20. Schnyder B., et al. T-cell-mediated cytotoxicity against keratinocytes in sulfamethoxazole-induced skin reaction. Clin. Exp. Allergy. 28:1998;1412-1417.
21. Park B.K., et al. Role of drug disposition in drug hypersensitivity: a chemical, molecular, and clinical perspective. Chem. Res. Toxicol. 11:1998;969-988.
22. Naisbitt D.J., et al. Cellular disposition of sulphamethoxazole and its metabolites: implications for hypersensitivity. Br. J. Pharmacol. 126:1999;1393-1407.
23. Boelsterli U.A. Xenobiotic acyl glucuronides and acyl CoA thioesters as protein-reactive metabolites with the potential to cause idiosyncratic drug reactions. Curr. Drug Metab. 3:2002;439-450.
24. Banks A.T., et al. Diclofenac-associated hepatotoxicity: analysis of 180 cases reported to the Food and Drug Administration as adverse reactions. Hepatology. 22:1995;820-827.
25. Dunk A.A., et al. Diclofenac hepatitis. BMJ. 284:1982;1605-1606.
26. Scully L.J., et al. Diclofenac induced hepatitis: three cases with features of autoimmune chronic active hepatitis. Dig. Dis. Sci. 38:1993;744-751.
27. Kretz-Rommel A., Boelsterli V.A. Mechanism of covalent adduct formation of diclofenac to rat hepatic microsomal proteins. Retention of the glucuronic acid moeity in the adduct. Drug Metab. Dispos. 22:1994;956-961.
28. Mitchell J.R., et al. Hepatic necrosis caused by furosemide. Nature. 251:1974;508-511.
29. Lagarriga J., et al. Rev. Gastroenterol. Mex. 42:1977;117-125.
30. Mitchell J.R., et al. The role of biotransformation in chemical-induced liver injury. Environ. Health Perspect. 15:1976;27-38.
31. Wong S.G., et al. The role of mitochondrial injury in bromobenzene and furosemide induced hepatotoxicity. Toxicol. Lett. 116:2000;171-181.
32. Takagi S., et al. Hepatotoxicity of DR-3438, tienilic acid, indacrinone and furosemide studied in vitro. Toxicol. Lett. 55:1991;287-293.
33. Grewal K.K., et al. Bromobenzene and furosemide hepatotoxicity: alterations in glutathione, protein thiols, and calcium. Can. J. Physiol. Pharmacol. 74:1996;257-264.
34. Williams D.P., et al. Induction of metabolism-dependent and -independent neutrophil apoptosis by clozapine. Mol. Pharmacol. 58:2000;207-216.
35. Williams D.P., et al. Neutrophil cytotoxicity of the chemically reactive metabolite(s) of clozapine: possible role in agranulocytosis. J. Pharmacol. Exp. Ther. 283:1997;1375-1382.
36. Pirmohamed M., et al. Metabolism and bioactivation of clozapine by human liver in-vitro. J. Pharmacol. Exp. Ther. 272:1995;984-990.
37. Uetrecht J.P. Metabolism of clozapine by neutrophils. Possible implications for clozapine-induced agranulocytosis. Drug Saf. 7:1992;51-56.
38. Pirmohamed M., Park B.K. Mechanism of action of clozapine-induced agranulocytosis: current status of research and implications for drug development. CNS Drugs. 7:1997;139-158.
39. Gardner I., et al. A comparison of the covalent binding of clozapine and olanzapine to human neutrophils in vitro and in vivo. Mol. Pharmacol. 53:1998;999-1008.
40. Uetrecht J.P. Prediction of a new drug's potential to cause idiosyncratic reactions. Curr. Opin. Drug Discov. Devel. 4:2001;55-59.
41. Gardner I., et al. A comparison of the oxidation of clozapine and olanzapine to reactive metabolites and the toxicity of these metabolites to human leukocytes. Mol. Pharmacol. 53:1998;991-998.
42. Boelsterli U.A. Disease-related determinants of susceptibility to drug-induced idiosyncratic hepatotoxicity. Curr. Opin. Drug Discov. Devel. 6:2003;81-91.
43. MacDonald M.G., et al. Potentiation of the toxic effects of acetaminophen in mice by concurrent infection with influenza B virus: a possible mechanism for human Reye's syndrome? Pediatr. Res. 18:1984;181-187.
44. Buchweitz J.P., et al. Underlying endotoxemia augments toxic responses to chlorpromazine: is there a relationship to drug idiosyncrasy? J. Pharmacol. Exp. Ther. 300:2002;460-467.
45. Wasserman W.W., Fahl W.E. Functional antioxidant responsive elements. Proc. Natl. Acad. Sci. U. S. A. 94:1997;5361-5366.
46. Schulze-Osthoff K., et al. Redox signalling by transcription factor NF-kB and AP-1 in lymphocytes. Biochem. Pharmacol. 50:1995;735-741.
47. Schiaffonati L., Tiberio L. Gene expression in liver after toxic injury: analysis of heat shock response and oxidative stress-inducible genes. Liver. 17:1997;183-191.
48. Bernelli-Zazzera A. Stress proteins and the liver. Ital. J. Gastroenterol. 25:1993;49-51.
49. Garcia-Ruiz C., et al. Role of oxidative stress generated from the mitochondrial electron transport chain and mitochondrial glutathione status in loss of mitochondrial function and activation of transcription factor nuclear factor-kB: studies with isolated mitochonrida and rat hepatocytes. Mol. Pharmacol. 48:1995;825-834.
50. Gruebele A., et al. Cytochrome P4502E1- and cytochrome P4502B1/2B2-catalyzed carbon tetrachloride metabolism: effects on signal transduction as demonstrated by altered immediate-early (c-Fos and c-Jun) gene expression and nuclear AP-1 and NF-kB transcription factor levels. Drug Metab. Dispos. 24:1996;15-22.
51. Schmidt K.N., et al. Induction of oxidative stress by okadaic acid is required for activation of transcription factor NF-kB. J. Biol. Chem. 270:1995;27136-27142.
52. Kwak M.K., et al. Modulation of gene expression by cancer chemopreventive dithiolethiones through the Keap1-Nrf2 pathway. Identification of novel gene clusters for cell survival. J. Biol. Chem. 278:2003;8135-8145.
53. Itoh K., et al. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem. Biophys. Res. Commun. 236:1997;313-322.
54. Itoh K., et al. Keap1 regulates both cytoplasmic-nuclear shuttling and degradation of Nrf2 in response to electrophiles. Genes Cells. 8:2003;379-391.
55. McMahon M., et al. Keap1-dependent proteasomal degradation of transcription factor Nrf2 contributes to the negative regulation of antioxidant response element-driven gene expression. J. Biol. Chem. 278:2003;21592-21600.
56. Dinkova-Kostova A.T., et al. Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants. Proc. Natl. Acad. Sci. U. S. A. 99:2002;11908-11913.
57. McMahon M., et al. The cap'n'collar basic leucine zipper transcription factor Nrf2 (NF-E2 p45-related factor 2) controls both constitutive and inducible expression of intestinal detoxification and glutathione biosynthetic enzymes. Cancer Res. 61:2001;3299-3307.
58. Ramos-Gomez M., et al. Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice. Proc. Natl. Acad. Sci. U. S. A. 98:2001;3410-3415.
59. Thimmulappa R.K., et al. Identification of Nrf2-regulated genes induced by the chemopreventive agent sulforaphane by oligonucleotide microarray. Cancer Res. 62:2002;5196-5203.
60. Heijne W.H., et al. Toxicogenomics of bromobenzene hepatotoxicity: a combined transcriptomics and proteomics approach. Biochem. Pharmacol. 65:2003;857-875.
61. Reilly T.P., et al. Expression profiling of acetaminophen liver toxicity in mice using microarray technology. Biochem. Biophys. Res. Commun. 282:2001;321-328.
62. Ruepp S.U., et al. Genomics and proteomics analysis of acetaminophen toxicity in mouse liver. Toxicol. Sci. 65:2002;135-150.
63. Fountoulakis M., et al. Modulation of gene and protein expression by carbon tetrachloride in the rat liver. Toxicol. Appl. Pharmacol. 183:2002;71-80.
64. Uetrecht J.P. New concepts in immunology relevant to idiosyncratic drug toxicity: the "danger hypothesis" and innate immunity. Chem. Res. Toxicol. 12:1999;887-895.
65. O'Brien P.J., et al. Repeated acetaminophen dosing in rats: adaptation of hepatic antioxidant system. Hum. Exp. Toxicol. 19:2000;277-283.
66. Shayiq R.M., et al. Repeat exposure to incremental doses of acetaminophen provides protection against acetaminophen-induced lethality in mice: an explanation for high acetaminophen dosage in humans without hepatic injury. Hepatology. 29:1999;451-463.
67. Mallis R.J., et al. Irreversible thiol oxidation in carbonic anhydrase III: protection by S-glutathiolation and detection in aging rats. Biol. Chem. 383:2002;649-662.
68. Benz F.W., et al. Dose dependence of covalent binding of acrylonitrile to tissue protein and globin in rats. Fundam. Appl. Toxicol. 36:1997;149-156.
69. Koen Y.M., Hanzlik R.P. Identification of seven proteins in the endoplasmic reticulum as targets for reactive metabolites of bromobenzene. Chem. Res. Toxicol. 15:2002;699-706.
70. Zhou L.X., et al. The covalent binding of [14C]Acetaminophen to mouse hepatic microsomal proteins: The specific binding to calreticulin and the two forms of thiol:protein disulfide oxidoreductase. Chem. Res. Toxicol. 9:1996;1176-1182.
71. Bourdi M., et al. Halothane-induced liver injury in outbred guinea pigs: Role of trifluoroacetylated protein adducts in animal susceptibility. Chem. Res. Toxicol. 14:2001;362-370.
72. Chou W.H., et al. Comparison of two CYP2D6 genotyping methods and assessment of genotype-phenotype relationships. Clin. Chem. 49:2003;542-551.